Khiron Advisor Featured as Part of Joint Investigation by 60 Minutes and the Washington Post on U.S. Opioid Crisis
TORONTO, Oct. 13, 2017 (GLOBE NEWSWIRE) -- Khiron Life Sciences Corp. (“Khiron” or the “Company”) reports that Matthew Murphy, Security and Compliance Advisor to Khiron, and former U.S. DEA Chief of Pharmaceutical Investigations, will be featured as part of a 60 Minutes and Washington Post joint investigation on the U.S. opioid crisis. The full report will be broadcast on CBS News this Sunday, October 15, 2017 at 7:30pm ET and 7:00pm PT, and featured in the Sunday Edition of The Washington Post. Link to the 60 Minutes trailer as below:
Matthew Murphy comments: “Contrary to what many are led to believe, in my professional experience as part of the U.S. DEA for 25 years, cannabis is not a gateway to heroin use. Opioid based medication is. It is time for governments and healthcare professionals to start evaluating alternatives to opioid based medications that are responsible for 91 deaths in the U.S. each day. To the best of my knowledge, no one has ever died from a cannabis overdose.”
The misuse of and addiction to opioids, including prescription pain relievers such as hydrocodone and oxycodone, is a serious national crisis that affects public health and is estimated to have a total economic burden in the U.S. of over $75 billion annually.
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is a Canadian integrated medical cannabis company with its core operations in Colombia. Khiron combines leading international scientific expertise, agricultural advantages, and branded product market entrance experience to address the unmet medical needs in a market of over 620 million people in Latin America.
On behalf of the Board of Directors
Chief Executive Officer
Direct: +57 (320) 4950326
Chief Financial Officer
Direct: +1 (705) 527 3564
Further information on the Company can be accessed through the link below:
FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, Khiron assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Released October 13, 2017